HLA-A24-binding KIF-derived peptide
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 28, 2011
Grant Date -
Mar 25, 2010
app pub date -
Aug 3, 2007
filing date -
Aug 4, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully